Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Porto – page 23

498 clinical trials in Porto, Portugal across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Porto at a glance
498
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

498 trials in Porto

Open in trial search

Breast cancer+1

Not recruiting

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Novartis Pharma AG

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Anxiety+1

Not recruiting

Comparison of oxazepam 50 mg orodispersible tablets and oxazepam 50 mg standard tablets in healthy volunteers to test if they work the same way in the body

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Oxazepam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Nicotine dependence

Not recruiting

Study of cytisinicline and moxifloxacin effects on heart electrical activity in healthy smokers with nicotine addiction

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Cytisinicline
  • Sponsor:Achieve Life Sciences Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Diabetic retinal oedema

Not recruiting

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Anxiety+1

Not recruiting

Study on the Bioequivalence of Oxazepam 10 mg Orodispersible Tablets Compared to Standard Tablets in Healthy Volunteers

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Oxazepam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on the Effects of Ribociclib and Endocrine Therapy for Patients with HR-Positive, HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Epileptic encephalopathy

Not recruiting

Title: Study of LP352 (bexicaserin) oral solution versus placebo for treating seizures in children and adults with Developmental and Epileptic Encephalopathies

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.

Congenital disorder of glycosylation

Not recruiting

Study on the Effects and Safety of GLM101 for Patients with PMM2-CDG

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:M1P dipotassium salt
  • Sponsor:Glycomine Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Porto

What the registry says about research in the country

01 Ophthalmology & Rare Diseases

Innovative research focusing on polypoidal choroidal vasculopathy and rare genetic conditions like PMM2-CDG, exploring new treatment approaches to improve patient outcomes.

  • Vision disorders
  • Genetic disorders
  • Treatment efficacy studies
02 Oncology & Hematology

Groundbreaking studies in chronic myelogenous leukemia, multiple myeloma, and advanced malignancies, including research on novel therapies for non-small cell lung cancer.

  • Blood cancers
  • Solid tumors
  • Immunotherapy
03 Dermatology & Immunology

Comprehensive research into conditions like hidradenitis suppurativa, plaque psoriasis, and pyoderma gangrenosum, evaluating new therapeutic approaches.

  • Inflammatory skin conditions
  • Autoimmune disorders
  • Novel biologics
04 Cardiology & Metabolic Disorders

Studies examining hypertrophic cardiomyopathy, familial hypercholesterolemia, and innovative treatments for obesity.

  • Heart conditions
  • Metabolic diseases
  • Weight management
05 Neurology & Genetic Disorders

Investigating treatments for Dravet Syndrome, menstrual migraine, and rare conditions like Niemann-Pick disease.

  • Neurological disorders
  • Rare diseases
  • Pain management
Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.